Doug Drysdale is a seasoned executive with extensive experience in the pharmaceutical and biotech industries. Currently serving as CEO of Cybin Inc. since August 2020, Drysdale focuses on advancing psychedelic pharmaceuticals for mental illness therapies. Additional roles include being a Board Member at SpineThera and Founder of Katogen LLC, which offers strategic consulting and transaction advisory services. Previous leadership positions include President & CEO at Tedor Pharma, Chairman at Pernix Therapeutics, and founding CEO at Alvogen. Drysdale's educational background includes a BSc (Hons) in Microbial & Molecular Biology from the University of East Anglia and an ONC in Medical Laboratory Sciences from Anglia Ruskin University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices